DrugBiological
Nogapendekin alfa inbakicept clinical trials
Also written ALT-803, N-803 and Anktiva.
- studies test it
- 79
- open now
- 18
- in phase 3
- 6
- first study started
- 2013
Keep track of what changes. Save the nogapendekin alfa inbakicept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Anktiva
- 12
Other names
Studies by the year they started
79 studies that test it; most in 2017 (17)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 17 |
| 2018 | 15 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 15 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 44
- Phase 2
- 57
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 51 · Other 28
ImmunityBio, Inc. (45) · National Cancer Institute (NCI) (6) · Washington University School of Medicine (5) · Altor BioScience (5) · Masonic Cancer Center, University of Minnesota (5) · University of Minnesota (2) · Thai Red Cross AIDS Research Centre (1) · Rockefeller University (1)
Often tested with
Tested in the same studies.
Paclitaxel (23) · Avelumab (22) · Albumin-Bound Paclitaxel (22) · Cyclophosphamide (21) · Fluorouracil (19) · Leucovorin (18) · ETBX-011 (17) · Capecitabine (17)
Studies
Open first, then newest update. How each study uses nogapendekin alfa inbakicept is read from its arms, and is right about nine times in ten.
Testing it · 79
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07574541Written as N-803
- PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT06239220Written as NAI
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06253494Written as N-803
- NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruitingPhase 2ImmunityBio, Inc.NCT07783789Written as Nogapendekin alfa inbakicept (NAI)
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingPhase 1ImmunityBio, Inc.NCT07217496Written as Nogapendekin Alfa Inbakicept (NAI)
- A Study to Examine Anktiva for the Treatment of COVID-19.RecruitingPhase 2ImmunityBio, Inc.NCT07123727Written as Anktiva
- N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular TherapyRecruitingEarly Phase 1Seth PollackNCT07261657Written as Nogapendekin Alfa Inbakicept
- Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNot yet recruitingPhase 1Washington University School of MedicineNCT07756593Written as N803
- A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT07085338Written as N803
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InRecruitingPhase 3ImmunityBio, Inc.NCT06745908Written as N-803
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingPhase 1/2Washington University School of MedicineNCT07355205Written as Nogapendekin alfa inbakicept
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingPhase 2ImmunityBio, Inc.NCT06710288Written as N-803
- Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingPhase 2ImmunityBio, Inc.NCT07628062Written as Nogapendekin Alfa Inbakicept (NAI)
- NAI for Sepsis With Persistent LymphopeniaNot yet recruitingPhase 2ImmunityBio, Inc.NCT07578558Written as Nogapendekin alfa inbakicept (NAI)
- A Study to Assess Anktiva in Patients With Long Covid-19.RecruitingPhase 2ImmunityBio, Inc.NCT07108036Written as N-803 (IL-15 Superagonist)
- Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecruitingPhase 1ImmunityBio, Inc.NCT05618925Written as N803
- Interleukin-15 to Promote Post-ART Control of HIVEnrolling by invitationPhase 2Michael Peluso, MDNCT07145164Written as N-803
- Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingPhase 2ImmunityBio, Inc.NCT06829823Written as N-803 and BCG
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedPhase 1/2National Cancer Institute (NCI)NCT05642195Written as N-803
- Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected PeopleCompletedPhase 1University of MinnesotaNCT02191098Written as ALT-803
See all 79 studies that test nogapendekin alfa inbakicept →
Given in every arm · 14 — nogapendekin alfa inbakicept is usual care beside what is tested
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT06149481Written as N-803
- IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07686380Written as N-803
- Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT06161545Written as N-803
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingPhase 2ImmunityBio, Inc.NCT07477366Written as N-803
- Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04340596Written as N-803 (IL-15 Superagonist)
- CIML NK Cell in Head & Neck CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT04290546Written as Interleukin-15 Superagonist (N-803)
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruitingPhase 2ImmunityBio, Inc.NCT06061809Written as N-803
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1ImmunityBio, Inc.NCT04898543Written as N-803 (Cohort 2 part B)
- Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedPhase 2National Cancer Institute (NCI)NCT04491955Written as N-803
- QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03563157Written as ALT-803
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedPhase 1/2ImmunityBio, Inc.NCT04927884Written as N-803
- N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerWithdrawnPhase 2National Cancer Institute (NCI)NCT05445882Written as N-803
- N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIVWithdrawnPhase 1/2University of MinnesotaNCT04144335Written as N-803 and bNAbs
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnPhase 2University of ArkansasNCT03003728Written as ALT-803
Codes
What other systems call nogapendekin alfa inbakicept · ClinicalTrials.gg INT006311
- MeSH (NLM) C582303nogapendekin alfa inbakiceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7TK323DLA0NOGAPENDEKIN ALFA INBAKICEPTConfirmed FDA, NLM
- NCI Thesaurus C205507Nogapendekin Alfa InbakiceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C582303 | nogapendekin alfa inbakicept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7TK323DLA0 | NOGAPENDEKIN ALFA INBAKICEPT | Confirmed FDA, NLM |
| NCI Thesaurus | C205507 | Nogapendekin Alfa Inbakicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.